Century Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Century Therapeutics, Inc. (Nasdaq: IPSC) on June 11, 2026. The report details the results of the Company's 2026 Annual Meeting of Stockholders held on the same date. The Company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
This filing is a corporate governance report and does not contain financial performance data. The text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Corporate Actions
- Authorized Share Increase: Stockholders approved an amendment to the Certificate of Incorporation to increase authorized common stock from 300,000,000 to 450,000,000 shares. The amendment was filed with the Delaware Secretary of State on June 11, 2026, and became effective on June 12, 2026.
- Share Count: As of the record date (April 16, 2026), there were 180,354,197 outstanding shares of common stock.
- Board Elections: Alessandro Riva, M.D., and Han Lee, Ph.D., M.B.A., were elected as Class II directors to serve until the 2029 Annual Meeting.
- Accountant Ratification: Stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the 2026 fiscal year.
Voting Results
| Proposal | For | Against | Abstentions | Broker Non-Votes |
|---|---|---|---|---|
| Election of Alessandro Riva, M.D. | 96,165,182 | 17,582,584 (Withheld) | N/A | 21,941,333 |
| Election of Han Lee, Ph.D., M.B.A. | 113,675,805 | 71,961 (Withheld) | N/A | 21,941,333 |
| Ratification of Ernst & Young LLP | 135,560,408 | 107,111 | 21,578 | 0 |
| Authorized Shares Amendment | 117,444,445 | 18,150,386 | 94,262 | 0 |
| Adjournment of Meeting | 117,181,181 | 18,419,826 | 88,087 | 0 |
Guidance, Outlook, and Risks
The filing does not contain management commentary on financial guidance, future outlook, specific risks, or contingencies. It strictly reports on the administrative outcomes of the Annual Meeting.
Key Facts for Investor Verification
- Verify the effective date of the authorized share increase (June 12, 2026) and the new total authorized share count (450,000,000).
- Confirm the tenure of the newly elected Class II directors (Alessandro Riva and Han Lee) through the 2029 Annual Meeting.
- Review the full text of the Certificate of Amendment filed as Exhibit 3.1 for specific legal terms regarding the share increase.
- Note the significant number of broker non-votes (21,941,333) on director elections, indicating shares held in street name where brokers lacked discretionary voting power.